WO2012128582A3 - Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant - Google Patents

Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant Download PDF

Info

Publication number
WO2012128582A3
WO2012128582A3 PCT/KR2012/002100 KR2012002100W WO2012128582A3 WO 2012128582 A3 WO2012128582 A3 WO 2012128582A3 KR 2012002100 W KR2012002100 W KR 2012002100W WO 2012128582 A3 WO2012128582 A3 WO 2012128582A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
same
compound
dehydrogenase type
steroid dehydrogenase
Prior art date
Application number
PCT/KR2012/002100
Other languages
English (en)
Other versions
WO2012128582A2 (fr
Inventor
In Hee Lee
Chang Min Park
Se Hoan Kim
Hee Il Chae
Doo Hyeok PYEON
Myoung Hyeon SHIN
Jeong Un HWANG
Soon Young Moon
Tae Young Ha
So Youn Kim
Hyuk Joon Choi
Myoung Hyun YOO
Jong Chan Lee
Young Seok Kim
Jae Keol Rhee
Original Assignee
Hyundai Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110025926A external-priority patent/KR20120108999A/ko
Priority claimed from KR1020120020455A external-priority patent/KR20120109297A/ko
Application filed by Hyundai Pharm Co., Ltd. filed Critical Hyundai Pharm Co., Ltd.
Publication of WO2012128582A2 publication Critical patent/WO2012128582A2/fr
Publication of WO2012128582A3 publication Critical patent/WO2012128582A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La présente invention concerne un composé inédit, ou un stéréo-isomère, ou un sel pharmaceutiquement acceptable de celui-ci et une composition pharmaceutique capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 (11β-HSD1) humaine en contenant. L'invention concerne un composé présentant une activité et une solubilité remarquables et pouvant être très efficacement formulé et administré, ainsi qu'une composition pharmaceutique capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine en contenant.
PCT/KR2012/002100 2011-03-23 2012-03-23 Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant WO2012128582A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2011-0025926 2011-03-23
KR10-2011-0025920 2011-03-23
KR1020110025926A KR20120108999A (ko) 2011-03-23 2011-03-23 인간 11-베타-히드록시스테로이드 탈수소효소 타입 1을 억제하는 화합물 및 이를 포함하는 약학조성물
KR20110025920 2011-03-23
KR10-2012-0020455 2012-02-28
KR1020120020455A KR20120109297A (ko) 2011-03-23 2012-02-28 인간 11-베타-히드록시스테로이드 탈수소효소 타입 1을 억제하는 화합물 및 이를 포함하는 약학조성물

Publications (2)

Publication Number Publication Date
WO2012128582A2 WO2012128582A2 (fr) 2012-09-27
WO2012128582A3 true WO2012128582A3 (fr) 2012-11-15

Family

ID=46879919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002100 WO2012128582A2 (fr) 2011-03-23 2012-03-23 Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant

Country Status (1)

Country Link
WO (1) WO2012128582A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057659A1 (fr) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Composés de quinoline sélectivement substitués
AU2014334551B2 (en) 2013-10-14 2018-05-10 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
CN107108597B (zh) 2014-10-31 2020-04-17 英立维尔英国有限公司 多巴胺d3受体拮抗剂化合物
US11104670B2 (en) * 2018-10-17 2021-08-31 Boehringer Ingelheim International Gmbh 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
MA53898B1 (fr) * 2018-10-17 2023-03-31 Boehringer Ingelheim Int Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament
EP3866854B1 (fr) * 2018-10-17 2022-08-10 Boehringer Ingelheim International GmbH Dérivés de 4-pyridinylméthyl-morpholine et leur utilisation comme médicament
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN114276280B (zh) * 2021-10-30 2023-10-31 苏州汉酶生物技术有限公司 一种手性苯丁胺醇磺酰胺类化合物的制备方法、制备其的中间体及制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154024A1 (en) * 2003-12-22 2005-07-14 Pfizer Inc Compounds useful in therapy
WO2006023844A2 (fr) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
JP2006131559A (ja) * 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
WO2006077025A2 (fr) * 2005-01-18 2006-07-27 F. Hoffmann-La Roche Ag Morpholines en tant qu'agonistes de 5ht2c
JP2011016742A (ja) * 2009-07-07 2011-01-27 Astellas Pharma Inc 環状アミノ化合物又はその塩

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154024A1 (en) * 2003-12-22 2005-07-14 Pfizer Inc Compounds useful in therapy
WO2006023844A2 (fr) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
JP2006131559A (ja) * 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
WO2006077025A2 (fr) * 2005-01-18 2006-07-27 F. Hoffmann-La Roche Ag Morpholines en tant qu'agonistes de 5ht2c
JP2011016742A (ja) * 2009-07-07 2011-01-27 Astellas Pharma Inc 環状アミノ化合物又はその塩

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEMCOMPOUND accession no. 3089177 *
DATABASE PUBCHEMCOMPOUND accession no. 3188324 *
DATABASE PUBCHEMCOMPOUND accession no. 3825918 *
DATABASE PUBCHEMCOMPOUND accession no. 564672 *
DATABASE PUBCHEMCOMPOUND accession no. 5651196 *
DATABASE PUBCHEMCOMPOUND accession no. 6243994 *
DATABASE PUBCHEMCOMPOUND accession no. 6737160 *
DATABASE PUBCHEMCOMPOUND accession no. 9417584 *
DATABASE PUBCHEMCOMPOUND retrieved from URL: http://pubchem.ncbi.nlm.nih.gov/search/search.cgi accession no. 1104591 *

Also Published As

Publication number Publication date
WO2012128582A2 (fr) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2012128582A3 (fr) Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
EP3715345A3 (fr) Procédé de préparation d'un inhibiteur de lfa-1 et polymorphe associé
IN2014KN00948A (fr)
WO2013091775A3 (fr) Utilisation de dérivés du cyclohéxanol comme principes actifs antimicrobiens
MY165087A (en) Neprilysin inhibitors
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
MY170935A (en) Neprilysin inhibitors
MX2013006802A (es) Inhibidores de neprilisina.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
MY183312A (en) Pharmaceutical formulation
MY187718A (en) Pharmaceutical formulations
WO2012106665A3 (fr) Disialyllacto-n-tétraose (dslnt) ou variants, isomères, analogues et dérivés associés, pour prévenir ou inhiber une maladie intestinale
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2013112959A8 (fr) Composés antifibrotiques et leurs utilisations
WO2013055687A3 (fr) R(+)-n-formyl-propargyl-aminoindane
WO2013093931A3 (fr) Nouveaux promédicaments de médicaments phénoliques
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
WO2013128379A3 (fr) Formes polymorphes cristallines de linagliptine
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2013019091A3 (fr) Composé d'inhibition de la 11β-hydroxystéroïde déshydrogénase de type 1, et composition pharmaceutique le comprenant
WO2011088160A3 (fr) Nouveaux inhibiteurs de cyp17
WO2011089126A3 (fr) Nouvelle composition
WO2012118308A3 (fr) Composition contenant un dérivé de pyrazole destinée à prévenir et à traiter les maladies cardiovasculaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12760521

Country of ref document: EP

Kind code of ref document: A2